ArticleCureus2025
A Review of Intracardiac Mass Cases Encountered Over a Two-Year Period.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracardiac mass is a rare condition that poses significant diagnostic and therapeutic challenges. Regardless of the pathological diagnosis, these cases are often difficult to manage, as patients typically present with urgent clinical symptoms at their initial visit. Most symptoms result from blood flow disturbances caused by a large intracardiac tumor. Furthermore, patients face a high risk of thromboembolism. Herein, we present five cases of intracardiac masses, including three malignant tumors, encountered over approximately two years. Each case had a different pathological diagnosis: angiosarcoma (n = 2), undifferentiated pleomorphic sarcoma (n = 1), benign myxoma (n = 1), and a simple ball thrombus (n = 1). Early and accurate diagnosis and treatment, ideally complete surgical resection, is the primary approach to managing intracardiac mass. However, extensive tumor resection can be difficult to achieve while preserving adequate cardiac function, especially in advanced-stage cases. In our series, surgical resection was not indicated for two patients (one with a ball thrombus and the other with angiosarcoma) due to impaired consciousness from multiple cerebral thromboembolism or advanced-stage sarcoma. The remaining three patients, diagnosed with myxoma, angiosarcoma, and undifferentiated pleomorphic sarcoma, underwent tumor excision. However, in the two malignant cases, early recurrence occurred, and postoperative management proved to be extremely challenging. The three patients with primary cardiac sarcoma received radiation therapy combined with chemotherapy or multiple chemotherapy regimens as either primary or secondary treatment. Of the two patients diagnosed with angiosarcoma, one died two months after admission without undergoing surgery, while the other died 11 months following tumor resection, highlighting the limited effectiveness of available treatments. The remaining patient, diagnosed with undifferentiated pleomorphic sarcoma, also received combination therapy with radiation and chemotherapy. In this case, the primary in the left atrium and a solitary metastasis to the left adrenal gland were relatively controlled with proton beam therapy. In cases of intracardiac mass, early diagnosis and prompt surgical excision are crucial. If the tumor is malignant, combined treatment with radiation and chemotherapy should be promptly considered as a second-line approach based on the tumor's characteristics and the extent of surgical resection. However, there are currently no curative treatments for either malignant or benign primary cardiac tumors other than complete tumor excision. Therefore, early-stage diagnosis is directly linked to improved prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.